Niclosamide is a potential candidate for the treatment of chemo-resistant osteosarcoma

Niclosamide Suppresses Migration and Invasion of Human Osteosarcoma Cells by Repressing TGFBI Expression via the ERK Signaling Pathway

(2022) Liang-Tsai Yeh et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

The anthelmintic drug niclosamide induces GSK-β-mediated β-catenin degradation to potentiate gemcitabine activity, reduce immune evasion ability and suppress pancreatic cancer progression

(2022) Yangyang Guo et al.   Cell Death & Disease

Mechanisms of Resistance to Conventional Therapies for Osteosarcoma

(2021) Louise Marchandet et al.   Cancers

Niclosamide and Pyrvinium Are Both Potential Therapeutics for Osteosarcoma, Inhibiting Wnt–Axin2–Snail Cascade

(2021) Young Yi et al.   Cancers

Targeting Wnt/β-catenin signaling by microRNAs as a therapeutic approach in chemoresistant osteosarcoma

(2021) Foroogh Hosseini et al.   BIOCHEMICAL PHARMACOLOGY

Preclinical Testing of a Novel Niclosamide Stearate Prodrug Therapeutic (NSPT) shows efficacy against Osteosarcoma

(2020) Gireesh B Reddy et al.   MOLECULAR CANCER THERAPEUTICS

Targeting Wnt/β‐catenin by anthelmintic drug niclosamide overcomes paclitaxel resistance in esophageal cancer

(2020) Wei Wei et al.   FUNDAMENTAL & CLINICAL PHARMACOLOGY

Targeting Molecular Mechanisms Underlying Treatment Efficacy and Resistance in Osteosarcoma: A Review of Current and Future Strategies

(2020) Ingrid Lilienthal et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Niclosamide-induced Wnt signaling inhibition in colorectal cancer is mediated by autophagy

(2019) Jiangbo Wang et al.   BIOCHEMICAL JOURNAL

Phase II trial to investigate the safety and efficacy of orally applied niclosamide in patients with metachronous or sychronous metastases of a colorectal cancer progressing after therapy: the NIKOLO trial

(2018) Susen Burock et al.   BMC CANCER

Niclosamide: Beyond an antihelminthic drug

(2018) Wei Chen et al.   CELLULAR SIGNALLING

The Antihelminthic Niclosamide Inhibits Cancer Stemness, Extracellular Matrix Remodeling, and Metastasis through Dysregulation of the Nuclear β-catenin/c-Myc axis in OSCC

(2018) Lin-Hong Wang et al.   Scientific Reports

Antibiotic anisomycin selectively targets leukemia cell lines and patient samples through suppressing Wnt/β-catenin signaling

(2018) Yong Li et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Current and future therapeutic approaches for osteosarcoma

(2017) Douglas J. Harrison et al.   Expert Review of Anticancer Therapy

Anthelmintic drug niclosamide enhances the sensitivity of chronic myeloid leukemia cells to dasatinib through inhibiting Erk/Mnk1/eIF4E pathway

(2016) Zhong Liu et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Niclosamide induced cell apoptosis via upregulation of ATF3 and activation of PERK in Hepatocellular carcinoma cells

(2016) Shunyan Weng et al.   BMC GASTROENTEROLOGY

Anthelmintic Niclosamide Disrupts the Interplay of p65 and FOXM1/β-catenin and Eradicates Leukemia Stem Cells in Chronic Myelogenous Leukemia

(2016) Bei Jin et al.   CLINICAL CANCER RESEARCH

Combined niclosamide with cisplatin inhibits epithelial-mesenchymal transition and tumor growth in cisplatin-resistant triple-negative breast cancer

(2016) Junjun Liu et al.   TUMOR BIOLOGY

Niclosamide and its analogs are potent inhibitors of Wnt/β-catenin, mTOR and STAT3 signaling in ovarian cancer

(2016) Rebecca C. Arend et al.   Oncotarget

Niclosamide enhances abiraterone treatment via inhibition of androgen receptor variants in castration resistant prostate cancer

(2016) Chengfei Liu et al.   Oncotarget

Niclosamide suppresses renal cell carcinoma by inhibiting Wnt/β-catenin and inducing mitochondrial dysfunctions

(2016) Juan Zhao et al.   SpringerPlus

Niclosamide inhibits the proliferation of human osteosarcoma cell lines by inducing apoptosis and cell cycle arrest

(2015) ZONGHUAN LI et al.   ONCOLOGY REPORTS

Inhibition of Wnt/β-catenin pathway by niclosamide: A therapeutic target for ovarian cancer

(2014) Rebecca C. Arend et al.   GYNECOLOGIC ONCOLOGY

Inhibition of the Wnt-β-catenin and Notch signaling pathways sensitizes osteosarcoma cells to chemotherapy

(2013) Yimin Ma et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

GSK3b-inhibitor lithium chloride enhances activation of Wnt canonical signaling and osteoblast differentiation on hydrophilic titanium surfaces

(2012) C. Galli et al.   CLINICAL ORAL IMPLANTS RESEARCH

Antihelminth Compound Niclosamide Downregulates Wnt Signaling and Elicits Antitumor Responses in Tumors with Activating APC Mutations

(2011) T. Osada et al.   CANCER RESEARCH

Redeployment-based drug screening identifies the anti-helminthic niclosamide as anti-myeloma therapy that also reduces free light chain production

(2011) F L Khanim et al.   Blood Cancer Journal